Arthritis Pain — Management, Treatments & Relief Guide — Symptoms, Causes & Treatment | MyMedicPlus

Arthritis pain refers to persistent, often chronic joint pain arising from the spectrum of conditions collectively termed arthritis — a group of over 100 conditions characterised by joint inflammation, cartilage damage, synovial pathology, or structural bone destruction. Arthritis pain is the most common cause of chronic pain and disability in the developed world, affecting over 350 million people globally (approximately 23% of adults in the United States have a physician-confirmed arthritis diagnosis), with associated costs in the United States alone exceeding $300 billion annually in direct medical costs and productivity losses. The two predominant sources are: osteoarthritis (OA) — a degenerative joint disease characterised by progressive articular cartilage erosion, subchondral bone remodelling, osteophyte formation, and low-grade synovial inflammation — with OA pain arising from multiple overlapping nociceptive mechanisms: subchondral bone exposure and microfractures (the bone is richly innervated; cartilage is avascular and aneural — so OA pain from cartilage loss paradoxically comes from surrounding innervated structures); intraosseous hypertension and periosteal stretching from osteophytes; synovial inflammation (even in OA); joint capsule distension from effusion; and periarticular muscle spasm. Rheumatoid arthritis (RA) — an autoimmune condition in which sustained synovial inflammation produces pain through inflammatory cytokines (TNF-α, IL-1β, IL-6, prostaglandins) sensitising nociceptors, and progressive articular destruction. Other important causes of arthritis pain include: gout (urate crystal-induced acute inflammatory arthritis — among the most severe acute pain conditions in clinical medicine); psoriatic arthritis, ankylosing spondylitis, reactive arthritis (spondyloarthropathies); septic arthritis (joint infection — emergency); and lupus arthritis. Central sensitisation — the amplification of pain signals within the central nervous system — plays an increasingly recognised role in chronic arthritis pain, explaining why structural severity on imaging often poorly correlates with subjective pain experience and why psychological interventions improve pain outcomes independently of structural disease.

Arthritis pain arises from multiple overlapping peripheral and central pain mechanisms that vary by arthritis type. Inflammatory cytokine-mediated peripheral sensitisation: in RA, psoriatic arthritis, ankylosing spondylitis, and gout, pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17) and arachidonic acid metabolites (prostaglandin E2, leukotriene B4) directly sensitise peripheral C-fibre and Aδ nociceptors within the synovium, joint capsule, and periarticular bone, producing primary hyperalgesia — whereby normally non-painful stimuli become painful and baseline pain threshold is reduced. Cartilage loss and subchondral bone damage in OA: full-thickness cartilage loss exposes the richly innervated subchondral bone plate to mechanical loading and repetitive microfractures; osteophytic periosteal stretching activates periosteal nociceptors; intraosseous hypertension from bone marrow oedema lesions (visible on MRI as a predictive marker of OA pain intensity); synovial effusion causes joint capsule distension, stretching mechanosensitive capsular afferents. Urate crystal-induced pain in gout: monosodium urate crystals activate the NLRP3 inflammasome in macrophages and synoviocytes, producing intense IL-1β-driven acute inflammatory synovitis — the most acute, severe joint pain in clinical medicine. Central sensitisation: in chronic arthritis, persistent peripheral nociceptive input causes central neuroplastic changes — N-methyl-D-aspartate (NMDA) receptor activation in the dorsal horn of the spinal cord, reduced descending inhibitory pathway activity, and cortical reorganisation — resulting in expanded pain receptive fields, allodynia (pain from normally non-nociceptive stimuli — light touch), and hyperalgesia; this explains why pain persists after successful surgical joint replacement in some patients. Risk factors: advancing age (strongest for OA); female sex (OA 2x higher risk in women post-menopause; RA 3x more common in women); first-degree family history; previous significant joint injury (post-traumatic OA — meniscal or cruciate ligament injury increases knee OA risk 3-5-fold); obesity (each BMI unit increase raises knee OA risk 11%; mechanically overloads cartilage and contributes adipokine-mediated synovial inflammation); repetitive occupational joint loading; and metabolic syndrome and hyperuricaemia (for gout — alcohol, high purine diet, diuretics).

Arthritis pain characteristics differ by type and help guide diagnosis. Osteoarthritis pain: mechanical in character — worsens with weight-bearing, sustained activity, and towards the end of the day; relieved by rest (though severe OA causes night pain and rest pain, indicating advanced disease); associated with brief morning stiffness typically under 30 minutes (post-inactivity stiffness — also occurs after prolonged sitting, known as 'gelling'); crepitus (audible or palpable grinding within the joint); bony joint swelling from osteophytes; antalgic gait and functional limitation. OA pain is most common in the knees, hips, hands (DIP joints — Heberden's nodes, first CMC joint), and spine. Rheumatoid arthritis pain: inflammatory in character — worst in the morning and after periods of rest (inflammatory mediator accumulation overnight); prolonged morning stiffness above 1 hour (a diagnostic criterion distinguishing RA from OA); symmetrical small joint involvement (MCPs, PIPs, wrists, MTPs); associated warmth, redness, and boggy synovial swelling; systemic features — profound fatigue (often the most disabling symptom), low-grade fever, weight loss, anaemia. Pain severity correlates with DAS28 score (Disease Activity Score — incorporating swollen joint count, tender joint count, ESR/CRP, and global health). Gout pain: acute, monoarticular, exquisitely tender (bed sheet touching the joint is unbearable), with erythema, swelling, and warmth — typically the first metatarsophalangeal joint (podagra — 50% of first attacks), ankle, or knee; onset often overnight; peak intensity within 12-24 hours. Chronic arthritis pain: disrupts sleep (nocturnal pain is near-universal in severe OA and active RA — a major independent predictor of depression and cognitive decline); amplifies catastrophising and fear-avoidance; causes fatigue, social withdrawal, and reduced quality of life. Pain assessment tools: Numerical Rating Scale (NRS 0-10), Visual Analogue Scale (VAS), WOMAC (Western Ontario and McMaster Universities — validated OA functional pain scale), DAS28 (RA activity), and McGill Pain Questionnaire for pain quality characterisation.

Comprehensive assessment of arthritis pain requires characterising the type, mechanism, and severity of pain alongside the underlying arthritis diagnosis to guide targeted treatment. Pain assessment tools: Numerical Rating Scale (NRS 0-10) — simple clinical tool; Visual Analogue Scale (VAS — 100 mm line) for pain research; WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index — 24-item scale measuring OA pain, stiffness, and function); DAS28 (Disease Activity Score in 28 joints — integrating swollen and tender joint counts, ESR or CRP, and patient global assessment — scores below 2.6 = remission; 2.6-3.2 = low disease activity; above 5.1 = high disease activity in RA); Brief Pain Inventory (BPI) and McGill Pain Questionnaire for multidimensional pain characterisation. Central sensitisation assessment: Pain Detect Questionnaire (PDQ — identifies neuropathic pain component); Pressure Pain Threshold (PPT) testing — reduced PPT at distant sites suggests central sensitisation; Temporal Summation and Conditioned Pain Modulation (CPM) testing in specialist pain settings. Structural imaging: plain radiographs (X-rays) of affected joints — assess joint space narrowing (cartilage loss), osteophytes, subchondral sclerosis and cysts (OA features); cortical erosions, periarticular osteoporosis (RA features); calcification (pseudogout CPPD). MRI: superior sensitivity for synovitis, bone marrow oedema lesions (BMELs — predictive of OA pain and cartilage loss), cartilage thickness mapping, tendon/ligament involvement, and bone erosion in RA before X-ray changes; musculoskeletal ultrasound (power Doppler ultrasound) detects active synovitis in RA and other inflammatory arthritides — immediately quantifies joint vascularity reflecting disease activity. Blood tests: ESR, CRP (acute phase reactants — elevated in active inflammatory arthritis, infection); FBC (anaemia of chronic disease — RA); RF (rheumatoid factor — positive in 70-80% of RA; also found in other conditions), anti-CCP antibodies (95% specific for RA — the most specific diagnostic test); serum urate (elevated in gout — note: may be normal during acute attack); ANA (antinuclear antibody) for lupus arthritis; uric acid plus synovial fluid microscopy for crystal arthropathies. Joint aspiration (arthrocentesis): synovial fluid analysis — essential to differentiate crystal arthropathy (negatively birefringent urate crystals — gout; positively birefringent calcium pyrophosphate crystals — pseudogout), septic arthritis (turbid fluid, WBC above 50,000/mm³ — culture and sensitivity), haemarthrosis, and inflammatory versus non-inflammatory effusion (WBC above 2,000/mm³ = inflammatory).

Arthritis pain management requires a multimodal approach targeting peripheral inflammation, structural joint disease, central sensitisation, and psychosocial factors simultaneously. Non-pharmacological treatments (should be offered to all patients as a foundation): therapeutic exercise — the single most evidence-based intervention for OA pain; quadriceps strengthening reduces knee OA pain by 20-40%; aquatic therapy and hydrotherapy provide pain relief with low joint load; aerobic exercise reduces RA disease activity and cardiovascular risk. Patient education and self-management programmes (Arthritis Care Expert Patient Programme) — improve pain self-efficacy and reduce disability. Physiotherapy and occupational therapy — manual therapy, joint protection techniques, splints, and adaptive aids. Psychological therapies — CBT and pain acceptance approaches reduce pain catastrophising and improve function independently of joint structural changes. Weight loss — every 1 kg weight loss reduces knee compressive force by 4 kg; 5% body weight loss significantly reduces knee OA pain. Pharmacological treatment — stepped approach: Step 1: topical NSAIDs (diclofenac gel 1% — 4x/day; or diclofenac solution 1.5% — 10 drops 3x/day); topical capsaicin 0.025-0.075% cream (depletes substance P from pain fibres; apply 3-4 times daily; initial burning sensation subsides after 2-4 weeks); topical methyl salicylate — first-line for OA of hands and knees (fewer systemic effects than oral NSAIDs; preferred in elderly). Step 2: paracetamol 500 mg-1 g up to 4 times daily — weak evidence for isolated OA; safer for long-term use than NSAIDs in elderly with renal or cardiovascular comorbidities. Step 3: oral NSAIDs (naproxen 500 mg BD, ibuprofen 400-800 mg TDS, celecoxib 100-200 mg BD — selective COX-2 inhibitor with lower GI risk; add PPI gastroprotection for all regular NSAID users; avoid in eGFR below 30, heart failure, recent MI, or with antithrombotic therapy). Duloxetine 60-120 mg/day — serotonin-noradrenaline reuptake inhibitor; licensed for chronic OA and musculoskeletal pain; particularly effective when central sensitisation features are present (allodynia, hyperalgesia, poor sleep, mood comorbidity). Step 4: tramadol 50-100 mg up to 4 times daily (weak opioid; avoid long-term; risk of dependence and falls in elderly). Intra-articular treatments: IA corticosteroid injections (triamcinolone acetonide 40 mg or methylprednisolone 40-80 mg) — rapid pain relief for 4-12 weeks; limit to 3-4 per joint per year to avoid cartilage toxicity; particularly effective for acute flares in inflammatory arthritis. IA hyaluronic acid (viscosupplementation) — knee OA; modest pain reduction at 4-12 weeks; NICE currently does not recommend routinely due to uncertain benefit size. IA platelet-rich plasma (PRP) — emerging evidence for OA; not yet NICE-recommended. RA-specific pharmacological treatment: treat-to-target — DAS28 remission or low disease activity within 6 months; methotrexate 15-25 mg/week + folic acid 5 mg/week (anchor DMARD); triple therapy (methotrexate + sulfasalazine + hydroxychloroquine); biologics for DMARD failure (adalimumab, etanercept, tocilizumab, abatacept); JAK inhibitors (baricitinib, upadacitinib). Joint replacement surgery: total hip and knee arthroplasty for end-stage OA — 95%+ success rate in appropriately selected patients; unicompartmental knee replacement for medial OA.

Seek emergency care for: a hot, severely swollen joint with fever — septic arthritis is a joint-destroying emergency requiring emergency joint aspiration and IV antibiotics; acute neurological symptoms (leg weakness, bladder or bowel changes) in ankylosing spondylitis or inflammatory arthritis (possible spinal cord involvement); or systemic symptoms suggesting vasculitis (rash, organ dysfunction) in rheumatoid arthritis. See a GP promptly for: new joint swelling and morning stiffness lasting over 30 minutes in multiple joints (possible rheumatoid or inflammatory arthritis — early DMARD treatment within 3 months of RA onset significantly reduces joint destruction); any acute intensely painful joint (gout or septic arthritis); or rapidly worsening pain with loss of function. All patients with chronic arthritis pain that limits daily activities should have a formal assessment by a rheumatologist or musculoskeletal specialist to ensure optimal treatment — many patients remain undertreated with simple analgesics when more effective therapies are available.

Undertreated arthritis pain leads to progressive physical and psychological deterioration. In osteoarthritis, chronic uncontrolled pain leads to progressive cartilage loss, subchondral bone damage, and eventually complete joint destruction — 'bone-on-bone' articulation requiring joint replacement surgery. Loss of joint mobility causes periarticular muscle wasting and weakness, further destabilising the joint and accelerating degeneration. In rheumatoid arthritis, uncontrolled synovitis causes bony erosions visible on X-ray within the first 1-2 years — erosive damage is irreversible and causes progressive deformity including ulnar deviation, swan-neck, and boutonniere deformities. Central sensitisation develops in chronic arthritis — the nervous system becomes hypersensitised and pain persists even after structural causes are addressed, making treatment increasingly difficult. Immobility from severe arthritis pain significantly increases cardiovascular risk, contributes to obesity, deepens depression, and accelerates bone loss (osteoporosis with fragility fracture risk). Sleep disturbance from nocturnal pain is near-universal in severe arthritis and is independently associated with depression, cognitive decline, and cardiovascular events. Falls and fall-related fractures — hip fractures in particular — become significant risks as joint instability, muscle weakness, and gait disturbance develop. Opioid escalation for poorly controlled chronic arthritis pain creates risks of dependence, constipation, respiratory depression, and paradoxical hyperalgesia. Depression and anxiety affect up to 30-50% of patients with chronic arthritis pain — significantly worsening pain perception, reducing treatment adherence, and increasing disability beyond the physical joint disease.

Maintain healthy weight — every kilogram lost reduces knee load by 4 kg during walking. Regular low-impact exercise (swimming, cycling, walking, hydrotherapy) strengthens muscles supporting joints and reduces pain 20-40%. Avoid repetitive joint trauma and overuse. Physical and occupational therapy teaches joint protection techniques. Heat therapy relaxes muscles and relieves stiffness; cold therapy reduces acute inflammation. A Mediterranean diet rich in omega-3s, antioxidants, and anti-inflammatory foods may modestly reduce arthritis pain. Adequate sleep and stress management are essential, as both worsen pain perception.